1. American Thoracic Society and Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. 2000;161:1376-1395.
  2. Andries K, Verhasselt P, Guillemont J. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227.
  3. Centers for Disease Control and Prevention. Drug-resistant TB. September 6, 2019. Accessed July 1, 2020.
  4. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2018. Accessed October 30, 2020.
  5. Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One. 2011;6(8):e23575.
  6. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep. 2010;7(3):143–151.
  7. Madariaga MG, Lalloo UG, Swindells S. Extensively drug-resistant tuberculosis. Am J Med. 2008;121(10):835-844.
  8. Matteelli A, Carvalho ACC, Dooley KE, et al. TMC207: the first compound of a new class of potent antituberculosis drugs. Future Microbiol. 2010;5(6):849-858.
  9. World Health Organization. Drug-Resistant TB Surveillance & Response. Global Tuberculosis Report 2019. Accessed July 2, 2020.
  10. World Health Organization. Tuberculosis. October 14, 2020. Accessed October 30, 2020.
  11. World Health Organization. Treatment of Tuberculosis Guidelines. 4th edition. March 24, 2020. Accessed July 2, 2020.
  12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 Update. Accessed July 2, 2020.
  13. Zignol M, van Gernert W, Falzon D, et al. Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis. 2011;52(7):901-906.
  14. Centers for Disease Control and Prevention. Tuberculosis — United States, 2018. Accessed October 1, 2020.